Parkinson Disease
Conditions
Keywords
Parkinson Disease, blood, plasma, metabolomics, spectroscopy, oxidative stress.
Brief summary
The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.
Detailed description
Oxidative stress has been implicated as a factor in the pathogenesis of Parkinson's disease (PD). The overall goal of this proposal is to use a novel metabolomics platform, based on near infrared biospectroscopy, to detect oxidatively modified blood plasma constituents. These spectral findings can be used to model the degree of oxidative stress with a modeled stress index that may distinguish PD cases from healthy elderly controls.
Interventions
OTHERBlood draw
Blood draw, two tubes, used for isolation of cell-free blood plasma
Sponsors
Michael J. Fox Foundation for Parkinson's Research
Molecular Biometrics, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
46 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
PD Subjects: 1. PostCEPT subjects with a diagnosis of PD based on UK Brain Bank criteria. 2. Willing and able to provide informed consent. Healthy Controls: 1. No current diagnosis or known history of a neurological disease/disorder. 2. Non-blood relative of a patient or subject at the site who has diagnosis of PD (may include healthy controls from the PROBE study). 3. No first degree relatives with diagnosis of PD 4. MoCA score \> 26. 5. Age \> 45. 6. Willing and able to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of the study is the correct classification of cases of PD and controls. This will be quantified as sensitivity and specificity. | Baseline and annually for two years |
Secondary
| Measure | Time frame |
|---|---|
| Determine impact of disease stage, age, gender, medications, cognitive scores, other laboratory measures (e.g. alpha-synuclein) and other clinical/demographic variables on plasma biospectra. | Baseline and annually for two years |
| Correlate plasma biospectra with dopamine transporter neuroimaging data. | Baseline and annually for two years |
Countries
United States
Outcome results
None listed